8
Validated projects
Validated across 8 projects; 7 yielded hit antibodies (success rate ~87.5%).
Technical Validation
Evaluating AI Antibody Design Through Validation Cases
Click.mAb. is designed not only to generate candidate sequences, but to connect epitope selection, sequence generation, structural assessment, and experimental validation into a reviewable R&D workflow. The following data come from representative cases shown on the website.
24+
Positive antibodies
Representative cases produced multiple experimentally confirmed candidates.
uM-nM
Affinity range
Candidate antibody affinity spans micromolar to nanomolar ranges.
Cryo-EM
Structural confirmation
A representative case confirmed the target epitope by cryo-EM.
Representative Evidence
De Novo Design Validation
In epitope-specific de novo design cases, the platform generates candidate sequences around target epitopes and validates results with BLI, blocking assays, and structural biology. Validated across 8 projects with 7 yielding hit antibodies (~87.5% success rate).
Affinity Maturation Validation
Wet lab validation of affinity maturation: the best matured antibody achieved KD 0.091 nM — a 12.2× improvement over the parent — with 31/32 candidates successfully expressed. Structure-driven cooperative mutation analysis delivers significant affinity gains from small libraries.
Humanization Performance
Representative antibody humanization cases reach 90%-95% humanness; representative nanobody humanization cases reach 89%-94% humanness while preserving or improving affinity in selected sequences.
CDR Diversity Engineering
For a 2 nM antibody based on a known active sequence (Trop2 target), CDR diversity engineering achieved CDR identity as low as 57% (target ≤70%). The result: 2 antibodies within 50% of parent affinity, 11 with normal expression, and 8 with SEC-HPLC purity matching or exceeding the parent — successfully achieving the sequence diversification goal.
R&D Workflow Continuity
The platform outputs candidate molecules, sequence analysis, structural assessment, and reports to support expression, screening, affinity optimization, and project review.
Related Capabilities
Do these data represent every project outcome?
No. Antibody R&D outcomes depend on target properties, epitope accessibility, assay systems, and project goals. These are representative cases that show validated directions and capability boundaries.
Can existing antibodies be further optimized?
Yes. The platform supports affinity maturation, antibody humanization, and nanobody humanization, including structural assessment, mutation suggestions, and candidate ranking for existing sequences.